Weekly diet for lowering ldl - weekly fare for move ldl

Weekly diet for lowering ldl
J. Fischman. Miedema, Salim S. The FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. John Chapman, Raimund Erbel, Peter Libby, Joel S. Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. CrossRef 323 John J. CrossRef 306 Niki Katsiki, Manfredi Rizzo, Dimitri P. Adobe Flash Player is required to view this feature. (2015) Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. , Ophuis, Ton Oude, Jukema, J. CrossRef 159 Dujrudee Chinwong, Jayanton Patumanond, Surarong Chinwong, Khanchai Siriwattana, Siriluck Gunaparn, John Joseph Hall, Arintaya Phrommintikul. , Blazing, Michael A. CrossRef 196 Mamoru Satoh, Yuji Takahashi, Tsuyoshi Tabuchi, Yoshitaka Minami, Makiko Tamada, Kan Takahashi, Tomonori Itoh, Yoshihiro Morino, Motoyuki Nakamura. Lavi, R. Kolh, S. (2015) Primary Prevention of Atherosclerotic Cardiovascular Disease. Adobe Flash Player is required to view this feature. Thus, clinicians must take these factors into account when applying the results of our trial in clinical practice. Gilbert. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. CI denotes confidence interval, CHD coronary heart disease, and MI myocardial infarction. (2015) Gaps in Guideline Implementation. CrossRef 237 Fatima Rodriguez, Joshua W. Michael White. CrossRef 3 Julian Hardy McLain, Andrew Jacob Alsterda, Rohit R. Adobe Flash Player is required to view this feature. Rader. (2014) Is High-Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low- to Moderate-Intensity Statin Therapy. Insights From In Vivo Assessments of Plaque, Vascular Remodeling, and Local Endothelial Shear Stress. CrossRef 316, P. 18 mmol per liter ) or less at the time of screening in the local hospital. Francis Hospital, Tulsa, Okla. In our study, the LDL cholesterol level was 33 mg per deciliter (0. (2016) Effects of Ethnicity on the Prevalence of Obstructive Sleep Apnoea in Patients with Acute Coronary Syndrome: A Pooled Analysis of the ISAACC Trial and Sleep and Stent Study. Oliver Chen, Sang-Woon Choi, Michael P. The benefit of high-dose atorvastatin as compared with standard-dose pravastatin emerged as early as 30 days and was consistent over time ( Figure 3 Figure 3 Hazard Ratio for the the Primary End Point of Death from Any Cause or a Major Cardiovascular Event at 30, 90, and 180 Days and at the End of Follow-up in the High-Dose Atorvastatin Group, as Compared with the Standard-Dose Pravastatin Group. Tonkin, J. American Heart Journal 168, 205-212. Management of Acute Coronary Syndrome. (2017) Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia. Wei, G. Kosiborod, F. (2015) Do statins reduce the risk of myocardial infarction in patients with heart failure. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. Messerli. Journal of Cardiovascular Pharmacology and Therapeutics 22:2, 99-104. CrossRef 376 Subhash Banerjee, Mazen Abu Fadel, Ravi Sarode, Lance Terada, Thomas Moritz, Ping Luo, Jeffrey Hastings, Emmanouil S. Sixty-nine percent of patients underwent percutaneous coronary intervention for the treatment of their index acute coronary syndrome before randomization. Koren, S. Eckard, Y. U. Kastelein, C. Biasucci, Filippo Crea, Ik-Kyung Jang. CrossRef 187 Elmar W Kuhn, Ingo Slottosch, Thorsten Wahlers, Oliver J Liakopoulos, Oliver J Liakopoulos. Chang, Y. CrossRef 279 P. (2014) Update in Therapeutic Approaches to Plaque Stabilization. (2014) All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels. CrossRef 276 S. Li, W. New and emerging data from clinical trials of statins. Adobe Flash Player is required to view this feature. Bailey, Susan S. Patients in clinical practice generally have more coexisting conditions than did our patients, and they may not tolerate a high-dose statin regimen as well as our patients did. (2014) Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review. Sidhu, William E. CrossRef 347 Behzad Yeganeh, Emilia Wiechec, Sudharsana R. Journal of the American College of Cardiology 65:24, 2638-2651. Dunn, Elaine M. (2015) Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. The investigators designed the trial and had free and complete access to the data. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Cassidy and N. Ballantyne. Adobe Flash Player is required to view this feature. For inhibiting hormones, see Releasing and inhibiting hormones. (2014) The Therapeutic Role of Niacin in Dyslipidemia Management. (2015) Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. Pfeffer, V. After the early separation of the clinical-event curves, we also observed a continued benefit of atorvastatin therapy throughout the follow-up period of two and one-half years ( Figure 2 ). (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Critical Reviews in Clinical Laboratory Sciences 54:1, 26-48. CrossRef 81 Iris Lin, Jennifer Sung, Robert J. Kao Yang, P. Prettin, S. (2016) Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. Morbach, D. Freeman, Geoffrey A. Endocrinology and Metabolism Clinics of North America 45:1, 171-184. -P. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Rouleau reports having received consulting fees and lecture fees from Novartis. Wang, Maria Svelto, Piero Portincasa. Conclusions Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. European Journal of Nuclear Medicine and Molecular Imaging 44:1, 141-150. CrossRef 121 Masoud Mardani. (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Whayne. (2015) Effect of Statins on Early and Late Clinical Outcomes of Carotid Endarterectomy and the Rate of Post-Carotid Endarterectomy Restenosis. McCulloch. Maisch, C. Juni, A. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Petersen. Kouz, M. Nicholls. Pankert, J. A. Feldman, Ik-Kyung Jang. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. S. (2015) How Do We Prevent the Vulnerable Atherosclerotic Plaque From Rupturing. (2017) Racial Differences in the Cholesterol-Lowering Effect of Statin. Smyth. Pankuweit, B. CrossRef 17 Ryo Naito, Katsumi Miyauchi, Hiroyuki Daida. T. CrossRef 153 Lulu Li, Minli Zhang, Fuxiang Su, Yang Li, Yali Shen, Jie Shen, Daqing Zhang. CrossRef 65 Yochai Birnbaum, Yumei Ye, Mandeep Bajaj. CrossRef 337 Alon Schaffer, Monica Verdoia, Lucia Barbieri, Toni Mustahsani Aprami, Harry Suryapranata, Paolo Marino, Giuseppe De Luca. -S. Free Full Text 172 Ryo Naito, Katsumi Miyauchi, Manabu Ogita, Shuta Tsuboi, Hirokazu Konishi, Tomotaka Dohi, Takatoshi Kasai, Hiroshi Tamura, Shinya Okazaki, Kikuo Isoda, Hiroyuki Daida. CrossRef 114 Anandita Agarwala, Zaid Kajani, Michael D. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. , Theroux, Pierre, Darius, Harald, Lewis, Basil S. Ande, Pawan Sharma, Adel Rezaei Moghadam, Martin Post, Darren H. C. (2014) Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. Milner, Lei Xing, Hang Lee, Bo Yu, Marc D. Drs. Walsh, M. Pedrazzini, A. Hilleman. Gandra, Stephen Djedjos, Nathan D. Shelton, Daniel J. U. CrossRef 53 Sephy Philip, Sumita Chowdhury, John R. Deharo, M. Kapadia, E. CrossRef 22 Daniel Hammersley, Mark Signy. 46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1. Bode, N. Nicholls. P. S. Pinkosky, Roger S. In addition, patients were also randomly assigned to receive with the use of a two-by-two factorial design a 10-day course of gatifloxacin or placebo every month during the trial. Cuisset. (2014) Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Tamargo, J. The reduction in clinical events with the more intensive lipid-lowering therapy was apparent as early as 30 days after the start of therapy. CrossRef 295 Yu Kataoka, Stephen J Nicholls. (2016) Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. (2015) Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys. CrossRef 14 Philip Joseph, Amorina Ishai, Venkatesh Mani, David Kallend, James H. (2016) Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention. (2014) The good and bad effects of statins on insulin sensitivity and secretion. Kees Hovingh, Rachel Laskey, Liffert Vogt, David A. Eight patients (0. Journal of the American College of Cardiology 63:25, 2889-2934. Acute Coronary Syndrome. B. (2016) Appropriate Level of Low-Density Lipoprotein Cholesterol for Secondary Prevention of Coronary Artery Disease. A. (2016) Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Patel, Eric A. CrossRef 31 Ishak A. Cannon. Adobe Flash Player is required to view this feature. Follow-up lasted 18 to 36 months (mean, 24). (2016) No evidence to support high-intensity statin in Chinese patients with coronary heart disease. Kedhi, M. Statin effects beyond lipid lowering -- are they clinically relevant. CrossRef 87 Elmar W Kuhn, Ingo Slottosch, Thorsten Wahlers, Oliver J Liakopoulos, Oliver J Liakopoulos. Blumberg, C. (2014) Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. , Giugliano, Robert P. In the Heart Protection study, statin treatment resulted in an LDL cholesterol level that was 40 mg per deciliter (1. (2014) Preprocedural statin use in patients undergoing percutaneous coronary intervention. Saseen. (2014) The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. CrossRef 145 Yu Kataoka, Jordan Andres, Rishi Puri, Peter Psaltis, Stephen J. (2016) An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. Virgil Brown. (2015) A 2-Year Follow-Up of Oxidative Stress Levels in Patients With ST-Segment Elevation Myocardial Infarction. 21 mmol per liter) or less, measured at the local hospital within the first 24 hours after the onset of the acute coronary syndrome or up to six months earlier if no sample had been obtained during the first 24 hours. CrossRef 342 Francisco Lopez-Jimenez, Vinaya Simha, Randal J. (2015) Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Adobe Flash Player is required to view this feature. Osman, Thomas F. CrossRef 258 M. (2015) Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study. : J. Boden. Miller. Wilson Tang. (2015) Knowledge of PCSK9 and Continued Educational Gaps. (2015) Newer treatment strategies: Mipomersen, Lomitapide and PCSK9. CrossRef 297 Caie Yang, Zhiqiang Sun, Yunpeng Li, Junping Ai, Qiyu Sun, Yaping Tian. Newton. (2014) Decade in review—dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemia. Bakris, John J. CrossRef 110 Harold E. Thiele, R. Foody. (2016) Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data. Adobe Flash Player is required to view this feature. Miller, William J. Optimizing Group-Sequential Designs with Focus on Adaptability: Implications of Nonproportional Hazards in Clinical Trials. De Luca. 2015. CrossRef 271 Koh Ono, Takahiro Horie, Tomohiro Nishino, Osamu Baba, Yasuhide Kuwabara, Takeshi Kimura. Huynh, E. Cannady, Ming-Dauh Wang, Stuart Friedrich, Jessica L. (2016) Two Randomized Controlled Pilot Trials of Social Forces to Improve Statin Adherence among Patients with Diabetes. Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines. CrossRef 149 Jong Shin Woo, Seung Joon Hwang, Hyun Soo Kim, Jin Bae Kim, Woo-Shik Kim, Kwon Sam Kim, Myung Ho Jeong, Weon Kim,, Saeid Ghavami. CrossRef 270 Takahisa Noto, Tomoki Kameyama, Takao Satoh, Makoto Nonomura, Takashi Nozawa, Hiroshi Inoue. Wenger. Zhao, P. (2015) Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials. (2015) Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia. (2014) Five-Year Prognosis After Endovascular Therapy in Claudicant Patients With Iliofemoral Artery Disease. Ballantyne, Laura A. Waters,, M. (2016) Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Sacks, P. Journal of the American College of Cardiology 66:11, 1273-1285. Journal of the American College of Cardiology 65, 846-855. It cannot be determined from this study whether this longer-term benefit was due to ongoing intensive lipid-lowering therapy or was the result of an early benefit in stabilizing vulnerable plaques with the early and intensive treatment after the acute event. CrossRef 45 Terry McCormack, Ricardo Dent, Mark Blagden. (2016) Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 64, 2645-2687. (2015) Statins in Acute Ischemic Stroke: A Systematic Review. Jacobson. Toth. Spertus. (2015) MicroRNAs and High-Density Lipoprotein Cholesterol Metabolism. Nicholls, Yu Kataoka. Alfonso, J. Kapadia, E. Fayad, Ahmed Tawakol. Wagner, S. (2014) Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. CrossRef 47 Mikkel Hougaard, Henrik Steen Hansen, Per Thayssen, Lisbeth Antonsen, Anders Junker, Karsten Veien, Lisette Okkels Jensen. (2016) The Role of Ezetimibe in the Treatment of Cardiovascular Disease. CrossRef 165 Patrick Wainwright, Aidan Ryan, Rasaq Olufadi, Christopher D Byrne. (2015) Long-Term Use of Cardiovascular Drugs. (2016) Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound. Menown. Most evidence suggests that statins are effective in preventing heart disease in those with high cholesterol, but no history of heart disease. (2015) Expanding the Evidence Base. Three interim assessments of efficacy and safety were carried out by the data and safety monitoring board. Rader and Pfeffer report having received consulting fees and lecture fees from Bristol-Myers Squibb. Statistical Analysis Although the trial was designed as a time-to-event study, the definition of noninferiority was arrived at through a consideration of two-year event rates. CrossRef 86 Elsie Gyang Ross, Nigam Shah, Nicholas Leeper, Saeid Ghavami. Journal of the American College of Cardiology 65:25, 2770. (2015) Polydatin Inhibits Formation of Macrophage-Derived Foam Cells. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. CrossRef 379 Mohamad Kenaan, Seth Milan, Herbert D. M. (2015) Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies. At the time of randomization, a median of seven days after the onset of the index event, the median LDL cholesterol levels were 106 mg per deciliter (2. Wascher, Heinz Drexel, Marianne Brodmann, Ernst Pilger, Alexander Rosenkranz, Erich Pohanka, Rainer Oberbauer, Otto Traindl, Franz Xaver Roithinger, Bernhard Metzler, Hans-Peter Haring, Stefan Kiechl. Dunning, E. Leiter, L. HANKINS. Journal of the American College of Cardiology 65, 1539-1548. CrossRef 383 Christopher M. Systematic review of randomized placebo-controlled trials to aid individual patient choice. Kong, Weihang Bao, Rana Fayyad, Rachel Laskey. Newsom. -Y. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Marked low-density lipoprotein cholesterol reduction below current National Cholesterol Education Program targets provides the greatest reduction in carotid atherosclerosis. Singh, A. CrossRef 381 Michal Vrablik, Daniel Holmes, Barry Forer, Andrew Juren, Pawel Martinka, Jiri Frohlich. Patients were seen for follow-up visits and received dietary counseling 8 at 30 days, at 4 months, and every 4 months thereafter until their final visit in August or September 2003. CrossRef 185 Cuihuan Xu, Dailong Fang, Xi Chen, Li Xinyue, Yu Nie, Yafei Xie, Yu Ma, Senyi Deng, Zhi Zhang, Xiangrong Song. Racine, H. CrossRef 370 Gian Marco Rosa, Federico Carbone, Antonello Parodi, Elena A. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Bays, W. (2014) The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. It also cannot be determined whether other differences between the two statins used explain the observed clinical benefit. CrossRef 311 P. Adobe Flash Player is required to view this feature. Wijns, A. (2016) A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Feinstein, Pardeep Jhund, Joseph Kang, Hongyan Ning, Aldo Maggioni, John Wikstrand, John Kjekshus, Luigi Tavazzi, John McMurray, Donald M. Adobe Flash Player is required to view this feature. Mansi. Badimon, J. Glucose Intake and Utilization in Pre-Diabetes and Diabetes, 245-268. Sousa Uva, G. Pancholia, Sundeep Mishra, Ravi R. CrossRef 324 L. 85 mmol per liter) lower in the atorvastatin group than in the pravastatin group. (2015) Present status of statin therapy. Journal of Indian College of Cardiology 5, S58-S65. Neumann, D. -H. 17,18 We studied patients who had been hospitalized for an acute coronary syndrome and enrolled them immediately after their condition had stabilized. Ekmekci. CrossRef 236 Tadateru Takayama, Takafumi Hiro, Yasunori Ueda, Satoshi Saito, Kazuhisa Kodama, Sei Komatsu, Atsushi Hirayama. Journal of the American College of Cardiology 65, 270-277. Serruys, P. (2016) Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies. Nicholls. European guidelines on cardiovascular disease and prevention in clinical practice. (2015) Effects of Statin Therapy on Clinical Outcomes of Survivors of Acute Myocardial Infarction with Severe Systolic Heart Failure. Journal of Indian College of Cardiology 5, S54-S57. Furneri, A. Ballantyne, Laura A. (2016) A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. 2016. (2016) Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data. Atherosclerotic plaque. Eligible patients were randomly assigned in a 1:1 ratio to receive 40 mg of pravastatin or 80 mg of atorvastatin daily in a double-blind, double-dummy fashion. Kelly and K. F. Holmvang, S. International Journal of Immunopathology and Pharmacology 27:3, 351-363. Nicholls. (2016) Perceived and actual risk of cardiovascular disease in patients with rheumatoid arthritis in Korea. Eapen, Nima Ghasemzadeh, Naveen Bellam, Neal Bhatia, Kiran Valiani, Jia Shen, Richard J. Data coordination was performed by the Nottingham Clinical Research Group (see the Appendix). Palmer. (2016) Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome. (2015) Treating Coronary Disease and the Impact of Endothelial Dysfunction. CrossRef 182 Keun-Sik Hong, Ji Sung Lee. Dadu, Christie M. Desai, Kaushang Gandhi, Mala Sharma, Harshad Amin, Trung M. Secemsky. Collet, J. (2014) Statins after acute coronary syndrome: a missed opportunity. F. CrossRef 58 Nuerbiye Tuerdi, Lu Xu, Baoling Zhu, Cong Chen, Yini Cao, Yunan Wang, Qiang Zhang, Zijian Li, Rong Qi. W. CrossRef 218 Valentina Kon, Haichun Yang, Sergio Fazio. (2015) Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. Sabry Hamza, Chanchal Kumar, Ser Mien Chia, Vidhya Anandalakshmi, Nicole Boo, Walter Strapps, Michael Robinson, Michelle Caguyong, Steven Bartz, Marija Tadin-Strapps, Alain van Gool, Shian-Jiun Shih. CrossRef 366 Stephen J Nicholls, Anthony D Pisaniello, Yu Kataoka, Rishi Puri. Tawakol, D. The results of the antibiotic component of the trial are not reported here. (2016) Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis. (2017) Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes. L. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Schulman, F. CrossRef 51 Ching-Yun Wei, Ruben G. Sergeant, S. (2016) Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. CrossRef 60 Sanghoon Shin, Hyung-Bok Park, Hyuk-Jae Chang, Reza Arsanjani, James K. CrossRef 330 P. (2017) Functional Heterogeneity of Nadph Oxidases in Atherosclerotic and Aneurysmal Diseases. White, Yuliya Lokhnygina, Craig Reist, KyungAh Im, Erin A. (2016) Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. CrossRef 195 Elvin Zengin, Christoph Bickel, Renate B. Nissen, Stephen J. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels. Colantonio, Vera Bittner. Journal of Cardiovascular Pharmacology and Therapeutics 19:2, 141-158. Califf. Urbina. Robinson. (2014) Relationship between cholesterol crystals and culprit lesion characteristics in patients with stable coronary artery disease: an optical coherence tomography study. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Tselepis. However, the risk was over 10-fold greater if cerivastatin was used, or if the standard statins (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) were combined with fibrate (fenofibrate or gemfibrozil) treatment. CrossRef 401 Dongdan Zheng, FanFang Zeng, Anping Cai, Huocheng Liao, Ling Liu, Ruofeng Qiu, Rulin Xu, Chun Xiao, Weiyi Mai. CrossRef 266 Tsuyoshi Ito, Hiroshi Fujita, Tomomitsu Tani, Nobuyuki Ohte. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. American Heart Journal 168, 682-689. Krueger. Agarwal, E. Patients were followed for 18 to 36 months, with an average follow-up of 24 months. (2016) Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Lerman, Amir Lerman. Marrs, Joseph J. Meredith, E. Protease inhibitors and statins taken together may increase the blood levels of statins and increase the risk for muscle injury (myopathy). Rehmel, Ping Yi, David S. Silber, J. Prevention of Cardiovascular Disease in Older Adults. CrossRef 123 Christopher P. Roos, Gregory J. Tran, Tzu Chun Kao, Toros Caglar, Karen M. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. (2015) Using inactivating mutations to provide insight into drug action. Verdier, G. (2014) What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug. Adobe Flash Player is required to view this feature. Jackson, R. Berns. 2015. Chan. CrossRef 183 Jimmy Jose, Faisal Abdullah Ali Al-Tamimi, Manal Mahmoud Helal, Beena Jimmy, Qasim Al Riyami, Ibrahim Al Busaidi. Kelbaek, M. Rudd, Tilmann M. Rudd, Zahi A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. CrossRef 362 Grace Huang, Leonardo Clavijo. Statins have been found to reduce cardiovascular disease (CVD) and mortality in those who are at high risk. The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. e7. F. (2015) Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. P. Quek, Guillermo Villa, Shravanthi R. Moschovitis, T. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Wasserman, Robert Scott, Marilyn Borgman, Stephen J. Ginsberg. Masud, C. Secondary end points were the risk of death from coronary heart disease, nonfatal myocardial infarction, or revascularization (if it was performed at least 30 days after randomization), the risk of death from coronary heart disease or nonfatal myocardial infarction, and the risk of the individual components of the primary end point. CrossRef 309 Peter P. (2015) Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. (2014) A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Yeh, Y. This article is about the group of cholesterol-lowering drugs. -C. (2016) Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. CrossRef 12 Meghan T. (2015) A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. Bang, Peter M. (2014) Use of ezetimibe results in more patients reaching lipid targets without side effects. Adobe Flash Player is required to view this feature. Jones, Penny Kris-Etherton, Geeta Sikand, Ralph La Forge, Stephen R. P. (2014) Clinical Features of Heart Failure and Acute Coronary Syndromes. 2016. Mahmood Hussain. Nguyen, Khoa M. Chai, Robin P. Granger. Lanthier, G. Tardif, C. (2014) Consensus statement on management of dyslipidemia in Indian subjects. (2014) Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. A. Dayasagar Rao, C. Cone Hospital, Greensboro, N. CrossRef 260 Matthew P. McComsey. (2015) Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The trial continued until 925 events had been reported to the coordinating center, after which time all patients were requested to return for a final study visit. S. Chew, Baris Gencer, Gerd Hasenfuss, Keld Kjeldsen, Patrizio Lancellotti, Ulf Landmesser, Julinda Mehilli, Debabrata Mukherjee, Robert F. CrossRef 336 Aldo P Maggioni, Elisa Rossi, Elisa Cinconze, Marisa De Rosa. Knowles. CrossRef 286 Xiaomeng Feng, Xia Gao, Yumei Jia, Heng Zhang, Qingrong Pan, Zhi Yao, Ning Yang, Jia Liu, Yuan Xu, Guang Wang, Xinchun Yang. Anderson. CrossRef 132 Kensuke Matsushita, Kiyoshi Hibi, Naohiro Komura, Eiichi Akiyama, Nobuhiko Maejima, Noriaki Iwahashi, Kengo Tsukahara, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Satoshi Umemura, Kazuo Kimura. (2016) Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. CrossRef 396 Kentaro Toyama, Toshihiko Nishioka, Ami Isshiki, Toshiyuki Ando, Yoshiro Inoue, Masato Kirimura, Tetsuo Kamiyama, Osamu Sasaki, Hiroyuki Ito, Yoshiaki Maruyama, Nobuo Yoshimoto. Aguirre, Jinwei Tian, Sining Hu, Tsunenari Soeda, Hang Lee, Iris McNulty, Seung-Jung Park, Yangsoo Jang, Abhiram Prasad, Stephen Lee, Shaosong Zhang, Italo Porto, Luigi M. J. Gilbert, S. Ryden. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Iyengar, Rajeev Gupta, Subhash C. Aronow, Joseph Naoum, Wunderly Douglas, Mitchiner James, Moscucci Mauro, Hitinder S. (2016) Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 135 Jung-Hee Lee, Dong-Ho Shin, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong. Roffi, L. CrossRef 267 Dan Atar, Seleen Ong, Peter J Lansberg. Although prior placebo-controlled studies have shown that a standard-dose statin is beneficial, 1-7 we demonstrated that more intensive lipid lowering significantly increased this clinical benefit. (2016) Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial. Medical Management of Coronary Artery Disease. CrossRef 278 Erisa Watanabe, Junichi Yamaguchi, Hiroyuki Arashi, Hiroshi Ogawa, Nobuhisa Hagiwara. CrossRef 141 Leonardo De Luca, Fabrizio Tomai. Mousa. Amsterdam, Nanette K. C. Pagliaro, S. (2015) Intensive Statin Therapy in NSTE-ACS Patients Undergoing PCI: Clinical and Biochemical Effects. (2017) Ezetimibe: an update on its clinical usefulness in specific patient groups. Kasliwal, Saumitra Kumar, Unni Krishnan, Sanjay Kalra, Anoop Misra, Usha Shrivastava, Seema Gulati. Kastelein, Christie M. Nguyen, Pierre Biron. Lloyd-Jones. A. Sawhney, Nakul Sinha, A. (2015) PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics. (2014) Lipids and lipid management in diabetes. Heidenreich. Harrison, Hak-Joon Sung. Boden. Chan, Alice P. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Stella-Maria Angelopoulou, Filitsa Konstantara, Christos Savopoulos, Apostolos I. (2016) Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. Roth, Corinne Hanotin, Daniel Gipe, Yunling Du, Anne-Catherine Ferrand, Henry N. (2016) Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution. French. Lovastatin, a compound isolated from Aspergillus terreus, was the first statin to be marketed. CrossRef 103 Sripal Bangalore, Rana Fayyad, John J. J. Iwere, Jonathan Hewitt. A. Landry. Adobe Flash Player is required to view this feature. This difference should translate into a 20 percent reduction in clinical events, which is very similar to the 16 percent reduction we observed and suggests that much of the benefit is attributable to the difference in the degree of LDL cholesterol lowering. Suryapranata, G. (2014) Efficacy and safety of ezetimibe plus atorvastatin therapy. 2014. (2014) Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. Rare reactions include myopathies such as myositis (inflammation of the muscles) or even rhabdomyolysis (destruction of muscle cells), which can in turn result in life-threatening kidney injury. Adobe Flash Player is required to view this feature. CrossRef 405 Robert Klempfner, Ilan Goldenberg, Enrique Z. Tari, C. De Ferrari, Giuseppe M. (2014) LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Sacks, Marc S. CrossRef 361 Yu Kataoka, Rishi Puri, Muhammad Hammadah, Bhanu Duggal, Kiyoko Uno, Samir R. Finally, patients had to have a total cholesterol level of 240 mg per deciliter (6. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. Bays. (2014) Acute Myocardial Infarction During Pregnancy. M. Grosdidier, V. (2014) Combination Therapy with Statins. The HMG-CoA reductase pathway, which is blocked by statins via inhibiting the rate limiting enzyme HMG-CoA reductase. Kastelein. (2016) Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. van Geuns, H. Laufer, F. Herrman, T. (2016) Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. Guertin, J. Adobe Flash Player is required to view this feature. R. CrossRef 290 Shunichi Nakamura, Shigenobu Inami, Koji Murai, Masamichi Takano, Hitoshi Takano, Kuniya Asai, Masahiro Yasutake, Wataru Shimizu, Kyoichi Mizuno. Rosano, Pasquale Perrone-Filardi. Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Miedema, Craig Strauss, Jeffrey J. Journal of the American College of Cardiology 65:25, 2768-2769. Pocock, Desmond G. 2015. Virani. CrossRef 288 Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka, Stephen J Nicholls. SAADE, GARY D. Wenger, Laurence Sperling. CrossRef 372 Ryo Nishio, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Takumi Inoue, Amane Kozuki, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi, Masamichi Iwasaki, Noritoshi Hiranuma, Akihide Konishi, Hiroto Kinutani, Junya Shite, Ken-ichi Hirata. CrossRef 43 Maria Drakopoulou, Konstantinos Toutouzas, Konstantinos Stathogiannis, Andreas Synetos, George Trantalis, Dimitrios Tousoulis. Stable Ischemic Heart Disease Stable Ischemic Heart Disease. Pfeffer, F. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Spence, G. K. Wong. CrossRef 382 Judith A Finegold, Charlotte H Manisty, Ben Goldacre, Anthony J Barron, Darrel P Francis. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Julian. Journal of the American College of Cardiology 66:2, 184-192. Jorgensen, Munir Pirmohamed. Froelicher, Ju-Hui Yun, Ye-Won Kim, Ju-Yang Jung, Chang-Hee Suh. (2014) Lipid-lowering effects of Danhong injection on hyperlipidemia rats. Storey, Stephan Windecker. 2015. Grundy, G. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. McGrew, C. (2015) PPAR-. CrossRef 217 Ricardo Ladeiras-Lopes, Stefan Agewall, Ahmed Tawakol, Bart Staels, Evan Stein, Robert J. Adobe Flash Player is required to view this feature. CrossRef 130 Ryo Naito, Katsumi Miyauchi, Hirokazu Konishi, Shuta Tsuboi, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Hiroshi Tamura, Shinya Okazaki, Kikuo Isoda, Hiroyuki Daida. The index event was high-risk unstable angina in approximately one third of the patients, myocardial infarction without electrocardiographic evidence of ST-segment elevation in approximately one third, and myocardial infarction with ST-segment elevation in one third. CrossRef 264 Tsuyoshi Nozue, Ichiro Michishita. Methods We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). CrossRef 63 Peter P. Matter, P. CrossRef 233 Gissette Reyes-Soffer, Henry N. Adobe Flash Player is required to view this feature. Drager, Chi-Hang Lee, Ferran Barbe. Adobe Flash Player is required to view this feature. Toth, George Thanassoulis, Curt D. (2014) Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. Whayne. Adobe Flash Player is required to view this feature. CrossRef 128 Tsuyoshi Nozue. CrossRef 363 Juan Chen, Jun Deng, Yuyan Zhang, Jiehong Yang, Yu He, Wei Fu, Panke Xing, Hai tong Wan. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 373 A. Statins are effective in decreasing mortality in people with pre-existing CVD. D. DeMicco, Chuan-Chuan Wun, Franz H. CrossRef 332 Tadasuke Chitose, Seigo Sugiyama, Kenji Sakamoto, Hideki Shimomura, Takuro Yamashita, Jun Hokamaki, Ryusuke Tsunoda, Shinya Shiraishi, Yasuyuki Yamashita, Hisao Ogawa. H. Wenger. Sirnes, J. W. (2017) Cholesteryl Ester Transfer Protein Inhibitors. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Nicholls, Pia Lundman, Philip J. Chayer, S. 2 percent) were lost to follow-up. Furberg. References References 1 Scandinavian Simvastatin Survival Study Group. Huff, A. (2014) Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease. J. Feldman, Peter H. (2017) Role of Niacin in Current Clinical Practice: A Systematic Review. CrossRef 273 Prakash Deedwania. Nguyen, Hoa T. CrossRef 357 Mamta Jaiswal, Ashley Schinske, Rodica Pop-Busui. CrossRef 122 Marco Roffi, Carlo Patrono, Jean-Philippe Collet, Christian Mueller, Marco Valgimigli, Felicita Andreotti, Jeroen J.


-H. Postoperative Care Following Major Vascular Surgery. Valgimigli, W. Issues in Data Analysis. (2014) Effect of an Educational Program in Primary Care: The Case of Lipid Control in Cardio-Cerebrovascular Prevention. VanWormer. (2015) Remodeling pattern is related to the degree of coronary plaque regression induced by pitavastatin: a sub-analysis of the TOGETHAR trial with intravascular ultrasound and coronary angioscopy. Noble, G. (2014) Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials. Preoperative statin therapy for patients undergoing cardiac surgery. (2014) HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. CrossRef 95 Udho Thadani, Quang Tuan Nguyen, Han Yaling. Journal of Taibah University Medical Sciences 11:4, 330-338. Ponikowski, P. Bonnet, T. (2015) Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. (2014) Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of Cardiovascular Pharmacology and Therapeutics 22:2, 133-141. The American Journal of the Medical Sciences 350:4, 330-337. Adobe Flash Player is required to view this feature. Brewer, Anna Svatikova, Sharon L. Toth. Luscher, J. LDL cholesterol levels were monitored, and the protocol specified that the dose of pravastatin was to increase to 80 mg in a blinded fashion if the LDL cholesterol level exceeded 125 mg per deciliter (3. (2015) Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Zeki, Saeid Ghavami. Kees Hovingh, John JP Kastelein, Patrick W. CrossRef 89 Tsuyoshi Nozue, Kazuki Fukui, Yutaka Koyama, Hiroyuki Fujii, Tomoyuki Kunishima, Hiroyuki Hikita, Kiyoshi Hibi, Akiyoshi Miyazawa, Ichiro Michishita. Mallya, Mark Friedman, Mary Panaccio, Andrew Koren, Peter Neumann, Joseph Menzin. Windecker, F. Reboussin, Christopher B. Gosselin, C. Colantonio, Vera Bittner. (2014) Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. Rouleau, P. F. Kerwin, Rebecca Taub, Jean-Claude Tardif, Ahmed Tawakol, Zahi A. Intensive lipid lowering with the 80-mg dose of atorvastatin, as compared with moderate lipid lowering with the 40-mg dose of pravastatin, reduced the hazard ratio for death or a major cardiovascular event by 16 percent. Kastelein, Bryan Williams, Juergen Armbrecht, Patrick Brunel, Yu Kataoka, Stephen J. (2015) Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. (2016) Managing the lipid profile of coronary heart disease patients. cohort. (2016) National Lipid Association Annual Summary of Clinical Lipidology 2016. 02586. 2016. CrossRef 173 Ichiro Kishimoto, Hisashi Makino, Yoko Ohata, Tamiko Tamanaha, Mayu Tochiya, Toshihisa Anzai, Kengo Kusano, Teruo Noguchi, Satoshi Yasuda, Hisao Ogawa. eLS, 1-12. (2014) Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Although the exact mechanism of the benefit cannot be established solely on the basis of our results, the extent of the benefit afforded by the 80-mg dose of atorvastatin is in keeping with what would be expected on the basis of the greater degree of lipid lowering produced by this regimen. (2016) The Impact of Statin on Influenza Vaccine Efficacy in the Elderly and Patients With Acute Respiratory Illness. CrossRef 188 Hyun Kuk Kim, Myung Ho Jeong, Hyeong Won Seo, Joon Ho Ahn, Kyung Hoon Cho, Young Joon Hong, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Kyung Woo Park, Hyo-Soo Kim, Sang Rok Lee, Jei Keon Chae. CrossRef 322 N. De Carlo, C. (2016) Lipid-lowering therapy stabilizes the complexity of non-culprit plaques in human coronary artery: a quantitative assessment using OCT bright spot algorithm. B. Roy, S. Fleg, Nanette K. Rosenson, Paul Muntner. CrossRef 48 Huabing Zhang, Jorge Plutzky, Maria Shubina, Alexander Turchin. (2014) Ongoing challenges for pharmacotherapy for dyslipidemia. Principles of Primary and Secondary Prevention of Cardiovascular Disease. Choudhury. McCollam, J. Windecker,. Tari. Nelson, P. (2014) Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials. (2016) Low-Density Lipoprotein Cholesterol Level and Statin Therapy in Patients With Acute Myocardial Infarction (Cholesterol Paradox). (2017) Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression. Journal of the American College of Cardiology 65, 278-280. G. 2015. Erdogan, A. DeFerrari, B. Scott Dean, Albeir Y. (2015) Atherosclerosis: Recent trials, new targets and future directions. 74 mmol per liter) before treatment in each group ( Figure 1 Figure 1 Median Low-Density Lipoprotein (LDL) Cholesterol Levels during the Study. -C. Cholesterol Metabolism and Vascular Disease. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. 2016. Tawakol. Joyal and Belder are employees of Bristol-Myers Squibb and have equity in the company. V. Juni, H. CrossRef 8 Aakash Garg, Abhishek Sharma, Parasuram Krishnamoorthy, Jalaj Garg, Deepti Virmani, Toishi Sharma, Giulio Stefanini, John B. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Sidhu, Peter P. Saucedo. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). F. Solow, Paul S. Investigators at TIMI, the sponsor, and members of the Nottingham Clinical Research Group performed data analysis jointly. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Li. Quek, Sohan Deshpande, Gill Worthy, Robert Wolff, Lisa Stirk, Jos Kleijnen, Shravanthi R. CrossRef 59 Sundararajan Srikanth, Prakash Deedwania. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Vehko, M. Brosseau, Walter A. P. Journal of the American College of Cardiology 63, 2491-2502. Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals. P. CrossRef 71 Takuro Miyazaki, Kazuo Tonami, Shoji Hata, Toshihiro Aiuchi, Koji Ohnishi, Xiao-Feng Lei, Joo-ri Kim-Kaneyama, Motohiro Takeya, Hiroyuki Itabe, Hiroyuki Sorimachi, Hiroki Kurihara, Akira Miyazaki. Kolhe, J. Adobe Flash Player is required to view this feature. (2017) Acute myocardial infarction. R. Revascularization was performed at least 30 days after randomization. Fayad, M. CrossRef 104 Sudeepta Dandapat, Jennifer G. CrossRef 70 Shigemitsu Tanaka, Yuji Ikari, Takeshi Ijichi, Gaku Nakazawa. CrossRef 213 P. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Patients were not permitted to be treated with any lipid-modifying therapy other than the study drug. CrossRef 161, Maciej Banach, Corina Serban, Amirhossein Sahebkar, Dimitri P. (2015) Statins in the Elderly: A Patient-Focused Approach. ) When it was determined that noninferiority was not demonstrated, the subsequent assessment of superiority was carried out with the use of two-sided confidence intervals. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. (2016) Should all surgery patients get statins pre-operatively. Sanoski, Elizabeth Phillips, Joseph J. (2015) Association Between Virtual Histology Intravascular Ultrasound Findings and Subsequent Coronary Events in Patients With Acute Coronary Syndrome. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Okin. (2014) Dietary modulators of statin efficacy in cardiovascular disease and cognition. A. W. Adobe Flash Player is required to view this feature. A. (2015) Secondary Prevention Strategy of Cardiovascular Disease Using Endothelial Function Testing. Katz, L. Knopp, I. -H. CrossRef 205 Cannon, Christopher P. Filippatos, C. Jiang, S. (2016) Statin treatment is associated with insulin sensitivity decrease in type 1 diabetes mellitus: A prospective, observational 56-month follow-up study. CrossRef 18 Yasuyoshi Kigawa, Takuro Miyazaki, Xiao-Feng Lei, Joo-ri Kim-Kaneyama, Akira Miyazaki. Lesperance, T. J. -J. CrossRef 69 Thomas Knickelbine, Matthew Lui, Ross Garberich, Michael D. F. European Heart Journal - Cardiovascular Imaging 15, 842-854. (2016) Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. W. As described previously, 11 men and women who were at least 18 years old were eligible for inclusion if they had been hospitalized for an acute coronary syndrome — either acute myocardial infarction (with or without electrocardiographic evidence of ST-segment elevation) or high-risk unstable angina — in the preceding 10 days. (2015) A novel therapeutic effect of statins on nephrogenic diabetes insipidus. Sabatine. CrossRef 25 Marie-Jeanne Bertrand, Jean-Claude Tardif. (2014) Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study. Endocrinology: Adult and Pediatric, 715-736. Nicholls, Kathryn A. -C. Sabatine, Daniel J. Adobe Flash Player is required to view this feature. P. (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Alessi, J. Suico, Ming-Dauh Wang, Stuart Friedrich, Jessica R. (2014) Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy. (2015) Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Blackman. Moretti, A. (2017) Plaque imaging to refine indications for emerging lipid-lowering drugs. (2015) The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women. (2015) Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes. Rupprecht, Stefan Blankenberg, Dirk Westermann,, Michael J Lipinski. Journal of the American College of Cardiology 66:5, 495-507. Rodes-Cabau, A. CrossRef 29 Juliana C. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI post coronary artery bypass graft clinical trial. -L. Taggart, L. The dose of either study drug could be halved in the event of abnormal liver-function results, elevations in creatine kinase levels, or myalgias. A. This rapid time frame is similar to that reported with statin treatment in the placebo-controlled Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial 16 and in prior observational studies. CrossRef 365 Dimitris Tousoulis, Costas Psarros, Michael Demosthenous, Rikhil Patel, Charalambos Antoniades, Christodoulos Stefanadis. (2015) Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. CrossRef 291 Amita Singh, Michael Davidson. Sultana, S. Supported by Bristol-Myers Squibb and Sankyo. Pepper, A. Multiple complex coronary plaques in patients with acute myocardial infarction. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. CrossRef 246 Leonilde Bonfrate, Giuseppe Procino, David Q. -J. A. Rallidis, John Lekakis. Nissen, Stephen J. P. Anyanwu, L. (2014) Eicosapentaenoic Acid Combined with Optimal Statin Therapy Improves Endothelial Dysfunction in Patients with Coronary Artery Disease. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Morange, M. Journal of the American College of Surgeons 220, 481-487. Lipids and Lipoproteins as Biomarkers of Vascular Complications in Diabetes and Their Modulation by Dietary Phytochemicals. Mulvagh. (2014) The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Although both drugs were generally well tolerated, there were significantly more liver-related side effects with high-dose atorvastatin than with standard-dose pravastatin. Jacobson. Manjunath, J. (2014) Lipid lowering with PCSK9 inhibitors. Cardiovascular Biomarker Assessment Across Glycemic Status. (2014) Risk of statin-induced rhabdomyolysis in patients with hepatic impairment. CrossRef 242 Sanjay Rajagopalan. 02586. CrossRef 230 Sripal Bangalore, Andrei Breazna, David A. Barter, J. J. Media in This Article Figure 1 Median Low-Density Lipoprotein (LDL) Cholesterol Levels during the Study. CrossRef 93 Mehmet Eyuboglu. (2014) Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. Witkowski,, J. Early statin treatment following acute myocardial infarction and 1-year survival. Falk, G. Head, P. (2014) Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies. (2016) Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. (2016) Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). (2016) Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice. (2016) Pleiotropic effects of statins: A boulevard to cardioprotection. Blood samples were obtained at randomization, at 30 days, at 4, 8, 12, and 16 months, and at the final visit for the measurement of lipids and other components that were part of the safety assessment. -L. 2016. Rules for stopping the study early in the event that the superiority of either treatment was established were not prespecified. Journal of the American College of Cardiology 65, 1103-1106. CrossRef 272 Stephan Windecker, Philippe Kolh, Fernando Alfonso, Jean-Philippe Collet, Jochen Cremer, Volkmar Falk, Gerasimos Filippatos, Christian Hamm, Stuart J. CrossRef 98 Thomas F. M. CrossRef 150 Laura J Corbin, Nicholas J Timpson. CrossRef 26 Yoshiyasu Minami, Taylor Hoyt, Jennifer E. (2015) Safety and efficacy of ezetimibe: A meta-analysis. Richter, Patrick Schauerte, Miguel Sousa Uva, Giulio G. Smith, A. CrossRef 32 Fatima Rodriguez, Shoutzu Lin, David J. Gitt, Dominik Lautsch, Jean Ferrieres, John Kastelein, Heinz Drexel, Martin Horack, Philippe Brudi, Brecht Vanneste, Peter Bramlage, Francois Chazelle, Vasilisa Sazonov, Baishali Ambegaonkar. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Sidhu, William E. European Heart Journal - Cardiovascular Pharmacotherapy 1, 157-165. Hanna, Jorge F. Journal of Clinical Lipidology 9:6, S1-S122. (2017) In-hospital statin underutilization among high-risk patients: delayed uptake of the 2013 cholesterol guidelines in a U. Singhal, Philippe Gabriel Steg, Gregory Ducrocq,. Zaugg, H. CrossRef 338 Silvio Garattini, Norberto Perico. Nonetheless, our findings suggest that patients with acute coronary syndromes who receive early and intensive lipid-lowering therapy continue to derive benefit in the chronic phase of atherosclerosis when high-dose statin therapy is maintained. -C. (2016) Current Controversies With Recent Cholesterol Treatment Guidelines. Deckers. Charland, Eric J. Journal of the American College of Cardiology 64, e139-e228. (2014) Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. (2016) A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. Drs. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Tang, Z. CrossRef 197 Richard Kones, Umme Rumana. Richter, P. F. L. Lai. (2016) Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing. (2015) Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome. Simoons, Jaap W. (2014) The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. Pham, Thu T. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. M. For the primary end point, the interaction P value was 0. F. : T. CrossRef 111 Jingbo Hou, Lei Xing, Haibo Jia, Rocco Vergallo, Tsunerari Soeda, Yoshiyasu Minami, Sining Hu, Shuang Yang, Shaosong Zhang, Hang Lee, Bo Yu, Ik-Kyung Jang. Bays, Peter H. Downs, John J. Stone. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Consumption of grapefruit or grapefruit juice inhibits the metabolism of certain statins. Hospital Practice 45:1, 16-20. European Heart Journal - Cardiovascular Pharmacotherapy 3:1, 58-67. Nissen, Venu Menon, Mingyuan Shao, Amy Hsu, George L. Ferrara, G. (2014) Evidence of Sample Use Among New Users of Statins. (2014) Management of ST-elevation myocardial infarction. (2016) The relationship between Lp(a) and CVD outcomes: a systematic review. Dobrev, J. Debanne, N. CrossRef 131 Kyung Hwan Kim, Cheol Hwan Kim, Myung Ho Jeong, Youngkeun Ahn, Young Jo Kim, Myeong Chan Cho, Wan Kim, Jong Jin Kim,. 2015. Ambrosy, Mihai Gheorghiade. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2016) Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. Khan, Aakash Deep. A pooled individual-level reanalysis of CORONA and GISSI-HF. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Intensive lipid lowering with the 80-mg dose of atorvastatin, as compared with moderate lipid lowering with the 40-mg dose of pravastatin, reduced the hazard ratio for death or a major cardiovascular event by 16 percent. Alan Brookhart. Dasseux, Z. CrossRef 125 2016. CrossRef 154 Mohamed Shehata, George Fayez, Ahmed Nassar. (2016) Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. CrossRef 99 M D Stillman, C E Aston, M H Rabadi. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. N. Patients who were receiving long-term lipid-lowering therapy at the time of their index acute coronary syndrome had to have a total cholesterol level of 200 mg per deciliter (5. Olsson. Journal of the American College of Cardiology 65:21, 2267-2275. , McCagg, Amy, White, Jennifer A. Measurements were made at the core laboratories listed in the Appendix. CrossRef 403 Hideki Kawai, Sadako Motoyama, Masayoshi Sarai, Hajime Ito, Hiroshi Takahashi, Hiroto Harigaya, Shino Kan, Junichi Ishii, Hirofumi Anno, Toyoaki Murohara, Yukio Ozaki. CrossRef 224 Lionel H. (2015) Protective and pathological roles of tissue factor in the heart. To convert values for LDL cholesterol to millimoles per liter, multiply by 0. Chen, C. (2014) Adding Coronary Computed Tomography Angiography to Invasive Coronary Angiography Improves Prediction of Cardiac Events. Bonnet, P. N. L. CrossRef 28 Marcelo J. Feinstein, Kim Allan Williams. Taniwaki, S. Jones, W. Shah, S. Jones, Yunling Du, Corinne Hanotin, Stephen Donahue. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2016) Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. (2016) Safety of atorvastatin in Asian patients within clinical trials. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. Preoperative statin therapy for patients undergoing cardiac surgery. -S. Opie. K. CrossRef 335 Ravi Jahagirdar, Haiyan Zhang, Salman Azhar, Jennifer Tobin, Sarah Attwell, Raymond Yu, Jin Wu, Kevin G. Abstract Background Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. Zamorano, S. Dr. Brilakis, Domenic Reda. Barter. CrossRef 284 Ahmed Farag, Deoraj Zamvar. (2015) Screening and Treatment by the Primary Care Provider of Common Diabetes Complications. CrossRef 312 Hou-Hsien Chiang, Fen-Yu Tseng, Chih-Yuan Wang, Chi-Ling Chen, Yi-Chun Chen, Ting-Ting See, Hua-Fen Chen, Yan Li. Achenbach, J. Adobe Flash Player is required to view this feature. Turner, Peng Yin, Anita Hanson, Richard FitzGerald, Andrew P. Tsilimbaris, Joan W. CrossRef 360 Takashi Miura, Yoshimitsu Soga, Yusuke Miyashita, Osamu Iida, Daizo Kawasaki, Keisuke Hirano, Kenji Suzuki, Uichi Ikeda. (2014) The correlation between serum lipid profile with carotid intima-media thickness and plaque. CrossRef 245 Naoyuki Abe, Yuichiro Kashima, Atsushi Izawa, Hirohiko Motoki, Souichiro Ebisawa, Yusuke Miyashita, Hiroshi Imamura, Uichi Ikeda. CrossRef 384 Nerea Hermida, Jean-Luc Balligand. Corrao, M. Virgil Brown. Ito, Harold E. (2015) On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). Saseen. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2014) Methodological issues of retrospective studies assessing health outcomes of potential clopidogrel-statin interaction. (2014) High-Density Lipoproteins and Coronary Artery Disease. Methods Patient Population Between November 15, 2000, and December 22, 2001, 4162 patients were enrolled at 349 sites in eight countries (see the Appendix). Adobe Flash Player is required to view this feature. Brown, J. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Journal of the American College of Cardiology 67:4, 353-361. Rehmel, Stephen J. 60 mmol per liter) in the high-dose atorvastatin group (P Full Text of Results. Watkins, L. (2014) Effect of a Hydrophilic and a Hydrophobic Statin on Cardiac Salvage after ST-elevated Acute Myocardial Infarction - A Pilot Study. Adobe Flash Player is required to view this feature. (2016) Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. Stable Ischemic Heart Disease Stable Ischemic Heart Disease. CrossRef 317 Yifei Liu, Elizabeth Unni. Schwartz, Markus Abt, Weihang Bao, David DeMicco, David Kallend, Michael Miller, Hardi Mundl, Anders G. Krolick, G. (2015) Phage-Display-Guided Nanocarrier Targeting to Atheroprone Vasculature. Tendera, A. Kappetein, A. CrossRef 215 Todd J. (2016) Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. CrossRef 148 Thomas F. Bacaksiz, E. CrossRef 80 Lea Duvnjak, Kristina Blaslov. -L. Arcoraci, L. Savage, Nicholas Ruggiero, David L. Biomarkers of Coronary Plaque Composition and Vulnerability. (2015) Clinical impacts of high-sensitivity C-reactive protein reduction for secondary prevention in Asian patients with one-year survivor after acute myocardial infarction. Intensive therapy with high-dose atorvastatin had a consistent beneficial effect on cardiac events, including a significant 29 percent reduction in the risk of recurrent unstable angina and a 14 percent reduction in the need for revascularization. Adobe Flash Player is required to view this feature. (2016) An update on management of the patient presenting with non-ST-elevation acute coronary syndromes. Tershakovec, Elizabeth Marrett. (2015) CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor. 2015. Among patients who had recently been hospitalized for an acute coronary syndrome, the more intensive regimen resulted in a lower risk of death from any cause or major cardiac events than did a more moderate degree of lipid lowering with the use of a standard dose of a statin. Gersh, D. (2014) Effect of Cardiovascular Drugs on Cardiovascular Events in 1599 Patients Followed in an Academic Outpatient Cardiology Practice. Lewis, T. Funderburg, G. Moschonas, Alexandros D. Lindsay. Adobe Flash Player is required to view this feature. Schmier. CrossRef 169 Konstantinos Tziomalos, Vasilios Giampatzis, Stella D. CrossRef 371 Veronica Ashton, Qiaoyi Zhang, Ning Jackie Zhang, Changgeng Zhao, Dena Rosen Ramey, David Neff, Andrew M. 2014. Raber, M. (2014) Use and misuse of statins after ACS: analysis of a prescription database of a community setting of 2,042,968 subjects. e1. Mussell, Caroline Carney, Jingsan Zhu, Wenli Wang, Andrea Troxel, Peinie Young, Victor Lawnicki, Swapnil Rajpathak, Kevin Volpp. (2016) Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Nicholls. (2014) Changes in Low-Density Lipoprotein Cholesterol Levels After Discharge for Acute Myocardial Infarction in a Real-World Patient Population. (2016) Gender differences in the prognostic role of uric acid and confounding factors. Birt, J. CrossRef 244 Roxana Mehran, Gennaro Giustino, Usman Baber. Virgil Brown, Ter